CWP
MRNA icon

Clark Wealth Partners’s Moderna MRNA Stock Holding History

Clark Wealth Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19K Hold
17
– – ﹤0.01% 472
2026
Q1 		$864 Hold
17
– – ﹤0.01% 536
2025
Q4 		$501 Hold
17
– – ﹤0.01% 529
2025
Q3 		$501 Hold
17
– – ﹤0.01% 529
2025
Q2 		$469 Buy
+17
New +$448 ﹤0.01% 488

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clark Wealth Partners's MRNA Position: Q2 2026 in Review

Clark Wealth Partners held its Moderna (MRNA) position steady in Q2 2026 at 17 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #472.

Clark Wealth Partners first reported a position in MRNA in Q2 2025 and has held it in 5 quarters since. 730 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Clark Wealth Partners held 17 shares of Moderna worth $1.19K as of Q2 2026.
  • Clark Wealth Partners left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Clark Wealth Partners's portfolio in Q2 2026, its #472 holding.
  • Clark Wealth Partners first reported a position in Moderna in Q2 2025 and has held it in 5 quarters since.
  • 730 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Clark Wealth Partners's 13F filing for Q2 2026, filed 28 Jul 2026.